Skip to main content

Carlos Molina Cateriano

Institutions of which they are part

Head of group
Stroke research
Vall Hebron Institut de Recerca

Carlos Molina Cateriano

Institutions of which they are part

Head of group
Stroke research
Vall Hebron Institut de Recerca

Projects

Malalties Neurovasculars (GRC)

IP: Joan Montaner Villalonga
Collaborators: Marta Aurora Rubiera Del Fueyo, Jorge Pagola Pérez Blanca, José Alvarez Sabin, Anna Penalba Morenilla, Maria Mar Hernandez Guillamon, Marc Ribó Jacobi, Maria Pilar Delgado Martínez, Carlos Molina Cateriano, Anna Rosell Novel, David Rodriguez Luna, Mª Ángeles Muchada López, Estevo Santamarina Pérez, Manuel Quintana Luque
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding: 48000
Reference: 2014 SGR 686
Duration: 01/01/2014 - 31/12/2016

Malalties neurovasculars

IP: Carlos Molina Cateriano
Collaborators: Laia Perez Lasarte
Funding agency: Instituto de Salud Carlos III
Funding: 53732
Reference: CM13/00265
Duration: 24/01/2014 - 23/01/2016

INVICTUS

IP: Joan Montaner Villalonga
Collaborators: Marta Aurora Rubiera Del Fueyo, Jorge Pagola Pérez Blanca, José Alvarez Sabin, Anna Penalba Morenilla, Maria Mar Hernandez Guillamon, Marc Ribó Jacobi, Maria Pilar Delgado Martínez, Carlos Molina Cateriano, Anna Rosell Novel, David Rodriguez Luna, Mª Ángeles Muchada López, Estevo Santamarina Pérez
Funding agency: Instituto de Salud Carlos III
Funding: 247695.66
Reference: RD12/0014/0005
Duration: 01/01/2013 - 31/03/2017

Malalties neurovasculars

IP: Carlos Molina Cateriano
Collaborators: -
Funding agency: Instituto de Salud Carlos III
Funding: 30000
Reference: INT12/295
Duration: 01/01/2013 - 31/12/2013

Related news

UMBRELLA, a consortium of over 20 public and private partners, kicks off this week with the aim of revolutionising the entire stroke care pathway in Europe by adopting a holistic approach that covers stroke diagnosis, prevention and care.

The Consortium will create a platform to facilitate a personalised management for stroke patients, enabling a more efficient personalized monitoring and patient follow up.

Funding is key to bringing the neuroprotective drug ApTOLL to market and providing a new therapeutic option for the patients.

Related professionals

Montse  Adell  Trape

Montse Adell Trape

General Surgery
Read more
Nadia Puertas  Porrino

Nadia Puertas Porrino

Main researcher
Read more
Mireia  Beltran  Porres

Mireia Beltran Porres

Growth and Development
Read more
Carina Lera Asensio

Carina Lera Asensio

Research technician
Transfusional Medicine
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.